This review synthesizes recent advances on major MDSC programs and highlights subtype-associated differences in their distribution patterns, immunosuppressive mechanisms, and clinical relevance across TNBC, HER2<sup>+</sup>, and HR<sup>+</sup>/Luminal breast cancer. Here, ERBB2 is linked to breast carcinoma.